Loading...
XSTO
XSPRAY
Market cap51mUSD
Oct 09, Last price  
10.70SEK
1D
2.29%
1Q
-28.38%
IPO
-67.58%
Name

XSpray Pharma AB (publ)

Chart & performance

D1W1MN
XSTO:XSPRAY chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
17.23%
Rev. gr., 5y
-47.34%
Revenues
0
3,640,000792,000331,546277,0000000000
Net income
-171m
L-39.95%
-12,091,000-4,097,000-13,198,387-23,098,000-45,837,000-52,303,000-96,702,000-130,267,000-179,667,000-285,523,000-171,443,000
CFO
-193m
L-13.13%
-12,964,000-1,744,000-11,039,934-17,746,000-34,237,000-47,792,000-51,607,000-110,179,000-203,275,000-222,367,000-193,163,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
URL
https://xspraypharma.com/
IPO date
Sep 28, 2017
Employees
26
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Scheeles väg 2
Solna, AB 171 65
SE
Address
Scheeles vag 2
Solna, AB 171 65
SE
Previous name
XSpray Microparticles AB
Previous name
XSpray Pharma AB

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT